DYN · Dyne Therapeutics, Inc.
$26.10
+0.12 (+0.46%)
At close · Aug 21
Market Cap
$4.85B
Shares
186.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$25.98
Open$26.33
Day$25.68–26.43
52W close$11.97–26.78
Avg vol 30d2.4M
Short int22.0M · 11.8% float · 7.2d
Short vol74%
Last earningsSep 3, 2024
DataSep 2020–Aug 2026
Filing10-Q · Jul 29
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 29, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+11%
above
RSI (14)
57
neutral
MACD trend
Negative
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+66%
trailing
YTD return
+33%
this year
Relative strength
+55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +49 funds added
Insider flow
Accumulating
Net +$65.9K over 90 days · 50% sells
Short interest
Rising
11.76% of float · ▲ +2.2% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
246 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
−3%
Y/Y
Free cash flow
$-405.1M
Balance sheet
$744.4M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
57
Neutral
MACD trend
Negative
Bearish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $23 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +49 funds added
Insider flow
Accumulating
Net +$65.9K over 90 days · 50% sells
Short interest
Rising
11.76% of float · ▲ +2.2% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
246 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12
Now $26 · 95%
Range high $27
vs 200-day avg +33%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DYN
this stock
Dyne Therapeutics, Inc.
|
$4.85B | +32.8% | — | — | 11.8% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.4% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DYN | +0.1% | +8.8% | +66.3% | +3.2% | +32.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.0% | +5.4% | +55.2% | +1.1% | +21.0% |
Key facts
CIK
1818794
CUSIP
26818M108
13F (30d)
237 filings
231 filers
Visit website
Investor relations